Search

Introduction: The trunks barks of Anogeissus leiocarpus contains multiple antihypertensive components and are, therefore, widely used for the treatment of hypertension. Objective: This study aimed to formulate capsules containing a freeze-dried aqueous extract of the trunk’s barks. Methodology: Three (03) capsule formulations were prepared using wet granulation from lyophilised aqueous extract of Anogeissus leiocarpus trunk bark, with different proportions of excipients including Corn starch used as the diluent, Polyvinylpyrrolidone K25 (PVP) used as binding agent and Magnesium stearate used as gliding agents. The filling of capsules was done using a semi-automatic capsule filler with empty capsules of size 3. The flow properties of the granules and the quality control were performed according to the European Pharmacopoeia 10th ed. Results/Discussion: All granules had good flow properties, and the F1 and F3 formulations had the best pharmaceutics characteristics according to the recommendations of the European Pharmacopoeia 10th ed. The mean levels of phenolic tracers were 0.039±0.0097 mg gallic acid equivalent per capsule (GAE/capsule) for the F1 formulation and 0.059±0.0063 mg GAE/capsule for the F3 formulation. Conclusion: This study allowed the galenic formulation of capsules based on extracts of good characteristic quality for the treatment of hypertension. [ABSTRACT FROM AUTHOR]

Sickle cell disease remains a major public health problem in Burkina Faso and Africa. For the management of this pathology in young children, the Institute for Research in Health Sciences has developed an herbal drug called FACA® syrup. The objective of this study was to verify the safety and pharmacological efficacy of this formulation for its use in the management of sickle cell disease. Acute and subacute oral toxicity tests were performed on Wistar rats in accordance with Organization for Economic Cooperation and Development test guidelines and anti-sickling activity of FACA® syrup was evaluated according to the Emmel test. In the acute test, FACA® syrup didn't cause mortality or any behavioral change at dose of 2000 mg/kg/b.w suggesting that the test product estimated LD50 is 5000 mg/kg b.w. The results of subacute toxicity study indicate that the daily administration of FACA® syrup during 28 days did not result in significant change on physical, haematological and biochemical parameters up to dose of 1000 mg/kg b.w. The evaluation of effect of FACA® syrup in vitro on sickling revealed that, FACA® syrup possesses a real antisickling activity. Regarding these results FACA® syrup would be considered as safe in both acute and subacute exposure and could be used in the management of sickle cell diseases. [ABSTRACT FROM AUTHOR]

Aims: This study investigated the antioxidant activity and the 90 days subchronic toxicity of the standardized LAMIC phytomedicine prototype based on aqueous extracts from Lannea microcarpa trunk bark. Methods: Three spectrophotometric methods were used to evaluated the antioxidant activity of LAMIC which were 2,2-Diphenyl-1- picrylhydrazyl (DPPH) free radical, 2,2'-azinobis(3-ethylbenzolin-6-sulphonate) (ABTS) radical scavenging assays and ferric reducing antioxidant power (FRAP) assays. For the standardized LAMIC subchronic toxicity study, male and female Wistar rats were used by daily oral administration at doses of 500, 1000 and 1500 mg/kg bw consecutively for 90 days. Results: The LAMIC extract exhibit better inhibitory activity against DPPH radical than ABTS radical with respective IC50 values of 45.38±3.21 µg/mL and 66.45±18.76 µg/mL, while FRAP assay exhibit antioxidant activity of 211.34±15.92 mmol EAA/g. Subchronic oral administration of LAMIC was well-tolerated at all tested doses. No behavioral and physiological changes and mortality were observed. The LAMIC extract did not present any impact on general hematological parameters and biochemical parameters. Moreover, no significant changes were raised in organ and body weight of treated groups compared to the Control group. Conclusion: These results support that LAMIC prototype was a valuable source of natural antioxidants and no toxicity was associated to it s long terms oral consumption in rats indicating a potential application as a cardiovascular protective formulation. [ABSTRACT FROM AUTHOR]

Aim of this study was to evaluate in vitro polyphenols content, antioxidant and antispasmodic properties of the aqueous extract and fractions of the trunk bark of Acacia nilotica. According to a survey conducted in rural Burkina Faso, Acacia nilotica var. adansonii (Guill and Perr). Ktze reported to be widely used in the treatment of gastrointestinal diarrhoea and parasitosis. A maceration of the powder of the trunk bark of the plant was carried out. Then the aqueous macerate obtain, was fractionated with dichloromethane, butanol and ethyl acetate successively. The phenolic compounds of the aqueous extract, butanol and ethyl acetate fractions was determinated. The antioxidant activity of aqueous extract and fractions was evaluated by the DPPH, ABTS and FRAP tests. The contractility test on smooth muscle was realized according to Magnus method. Assay of the extracts revealed a high content of polyphenols, tannins and flavonoids. The aqueous extract, the butanol fraction and the ethyl acetate fraction demonstrated a high antioxidant capacity. Aqueous extract showed a better antispasmodic effect of acetylcholine contraction induction at 1 µM (IC50 = 13.02 µg / mL) and for BaCl2 at 160 µg / mL (IC50 = 117.2 µg / mL). The aqueous extract of Acacia nilotica and his fractions had antioxidant properties. Only aqueous extract proven better antispasmodic property. Hence its use in traditional medicine in the treatment of diarrhoea. [ABSTRACT FROM AUTHOR]